C5orf32 Inhibitors
Inhibitors of C5orf32 function by interfering with specific signaling pathways that lead to its activation or modification, thus reducing its activity. For example, certain compounds target the phosphatidylinositol 3-kinase (PI3K) pathway, resulting in decreased phosphorylation of downstream effectors, including Akt. Given that Akt may be responsible for phosphorylating C5orf32, the inhibition of PI3K leads to reduced phosphorylation and, therefore, decreased activity of C5orf32. Similarly, inhibitors of the mitogen-activated protein kinase (MAPK) pathways, such as the extracellular signal-regulated kinase (ERK) and p38 MAPK, also contribute to the downregulation of C5orf32. By preventing the activation of MEK, which is upstream of ERK, or directly inhibiting p38 MAPK, these compounds reduce the signaling that could be involved in the regulation of C5orf32's phosphorylation state and its subsequent activity.
Additionally, other inhibitors target various kinases known to influence the activity of multiple proteins, potentially including C5orf32. Inhibition of mTOR, for instance, can lead to a broad reduction in the activity of proteins regulated by mTOR signaling pathways, which might implicate C5orf32 if it falls under mTOR's regulatory scope. Compounds that inhibit Src family kinases or multiple kinases, like multikinase inhibitors, can also lead to a decrease in C5orf32 activity by reducing the phosphorylation that would otherwise occur through these kinases. Furthermore, proteasome inhibition has been noted to cause increased cellular stress, which could impact proteins sensitive to proteostatic mechanisms, including C5orf32.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of phosphatidylinositol 3-kinases which indirectly leads to a reduction in Akt phosphorylation, a kinase that may phosphorylate C5orf32, thus reducing its functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Acts as a covalent inhibitor of phosphatidylinositol 3-kinases, thereby decreasing downstream signaling that includes Akt activation, potentially decreasing phosphorylation of C5orf32 and its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This compound acts as an inhibitor of MEK, which in turn decreases ERK pathway activity. Reduced ERK signaling could result in lower functional activity of C5orf32 if it is a downstream effector. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Inhibits MEK1/2 leading to decreased activation of the ERK pathway, which can affect the phosphorylation state and activity of C5orf32 if it is modulated by this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that can lead to reduced activity of C5orf32 by inhibiting pathways that may regulate its phosphorylation or other post-translational modifications. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK) which may impact the functional activity of C5orf32 by interfering with stress-activated signaling pathways that could modulate its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can lead to decreased activity of downstream proteins, potentially affecting C5orf32 activity if it is regulated by mTOR signaling pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
This Src family kinase inhibitor could diminish the activity of C5orf32 by inhibiting upstream kinases that may phosphorylate and activate C5orf32. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that may lead to increased cellular stress, potentially decreasing the functional activity of C5orf32 if it is sensitive to proteostatic mechanisms. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
As an EGFR tyrosine kinase inhibitor, this compound may decrease signaling pathways that could phosphorylate and modulate the activity of C5orf32. | ||||||